MedTrace Logo

Managing Insulin Pumps for Exercise - Study 1

NCT01401127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2011-11-08

No results posted yet for this study

Summary

People with Type 1 Diabetes Mellitus (T1DM) like to take part in sport and exercise, but problems with metabolism and blood glucose control can make this difficult. Some people with T1DM administer their insulin via an insulin pump, also know as continuous subcutaneous insulin infusion (CSII) therapy, in which a background or basal level of insulin is constantly infused under the skin by a special pump, with bolus doses of insulin given to accompany food. Clinical experience suggests that this may be particularly useful for managing diabetes for exercise, but there is limited experimental evidence to support this. The aim of this research , which is divided into three parts, is to investigate the hypothesis that the physiological response to sub-maximal (moderate) exercise of a person with type 1 diabetes treated with CSII, can be made to approximate more closely to the physiological response of a healthy individual by a prior reduction of their basal insulin infusion rate. This first part of the research is designed to compare metabolic response to exercise between people without diabetes and people with T1DM running there insulin pump at the usual basal rate.

Conditions

  • Type 1 Diabetes Mellitus

Sponsors & Collaborators

  • Animas Corporation

    collaborator INDUSTRY

  • Buckinghamshire Healthcare NHS Trust

    lead OTHER

Principal Investigators

  • Ian W Gallen, MD FRCP · Buckinghamshire Healthcare NHS Trust

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01401127 on ClinicalTrials.gov